AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Purchases of Investments
Cash used to buy marketable securities and other investments.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments declines year over year
Q1 FY2026 purchases of investments of $2.7M (cash outflow) fell 87.9% year over year, behind the -61.5% change in trailing-twelve-month purchases of investments. Sequentially, it fell 67.5% from the prior quarter. Over 3 fiscal years it compounded at -21.0% a year.
Context
- Purchases of investments grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -87.9% toward the trailing-twelve-month pace of -61.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (46.19M) USD
- Year-over-year change
- +1.2%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (46.19M) | +1.2% |
| FY2024 | 2024-12-31 | (46.75M) | +64.6% |
| FY2023 | 2023-12-31 | (132.18M) | -40.9% |
| FY2022 | 2022-12-31 | (93.84M) | -21.4% |
| FY2021 | 2021-12-31 | (77.27M) | — |
Purchases of Investments vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 purchases of investments of $26.59M is the 4th largest of the 6 companies compared; the peer median is $55.26M.
- Its year-over-year change of -61.5% is the lowest of 3, against a peer median of +3408.1%.
- Over three fiscal years its annual growth of -21.0% compares with a peer median of +60.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $433.45M | +6853.0% | — | — | |
| LTM Mar 2026 | $151.68M | -36.8% | +60.1% | — | |
| LTM Jun 2026 | $55.26M | — | — | 55257.0% | |
| LTM Mar 2026 | $26.59M | -61.5% | -21.0% | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANTX) | $55.26M | +3408.1% | +60.1% | 0.0% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 974K | 4.39M | 8.41M | 8.34M | 6.25M |
| Change in Working Capital | 32K | 3.72M | 5.83M | (3M) | 164K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 417K | 2.5M | 553K | 641K | (296K) |
| Other Working Capital | (385K) | 1.22M | 5.28M | (3.64M) | 460K |
| Other Non-Cash Items | 53K | (615K) | (2.8M) | (3.28M) | (1.07M) |
| Operating Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.27M) | (93.84M) | (132.18M) | (46.75M) | (46.19M) |
| Sales of Investments | 27.25M | 72.07M | 88.9M | 101.34M | 74.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.02M) | (21.77M) | (43.28M) | 54.59M | 28.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 70.37M | 84.53M | 372K | 113K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.2M) | (11K) | 465K | 0 | 0 |
| Financing Cash Flow | 78.54M | 70.36M | 84.99M | 372K | 113K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.03M | 15.12M | (11.57M) | 5.7M | (1.41M) |
| Free Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.